Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 2Head & Neck 2Genitourinary 2Sarcoma 1Other solid neoplasm 1NET 1Gynecologic 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Sarcoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Quality of Life 2tislelizumab 1surufatinib 1regorafenib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1copper dotatate CU-64 1Surveys and Questionnaires 1Poly(ADP-ribose) Polymerase Inhibitors 1Patient Reported Outcome Measures 1PM 01183 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Irinotecan 1Immunotherapy 1Fluorodeoxyglucose F18 1FAPI-46 1Drug Therapy 1Cyclophosphamide 1Cryotherapy 1Control Groups 1Clinical Trials, Phase II as Topic 1Biological Therapy 1Betaine 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × regorafenib × NET × Clear all
NCT03475953 2023-03-03

REGOMUNE

Institut Bergonié

Phase 1/2 Unknown
747 enrolled
BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡